Status:
COMPLETED
Safety and Efficacy of Intrathecal Rituximab in 16 Children of Stage Ⅲ、ⅣNon-Hodgkin Lymphoma
Lead Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Conditions:
Lymphoma, Non-Hodgkin
Child, Only
Eligibility:
All Genders
1-14 years
Brief Summary
Objective: This study demonstrated that the efficacy and safety of intrathecal(IT) rituximab in the treatment of stage Ⅲ and Ⅳ non-Hodgkin lymphoma(NHL) in children. Methods: We reported 16 children ...
Detailed Description
Malignant lymphoma is one of the most common malignancies in children, with approximately 60 percent of cases being B-cell, non-hodgkin lymphoma (NHL) . NHL in children progresses rapidly, prone to bo...
Eligibility Criteria
Inclusion
- Clinical diagnosis of B lymphocyte NHL
- Age≤ 18 years old
- Normal heart and kidney function
Exclusion
- Heart, liver and kidney diseases
- Allergic to rituximab
Key Trial Info
Start Date :
September 30 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 30 2022
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT06190457
Start Date
September 30 2015
End Date
August 30 2022
Last Update
January 5 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.